Histone-modifying enzyme inhibitors, such HDAC and histone methyltransferase inhibitors, may one day be turned into potent therapies for MS, addressing both the autoimmune and neurodegenerative aspects of the disease. This evidence concerns the gene HDAC9 and myeloid sarcoma.